{"altmetric_id":3716971,"counts":{"readers":{"mendeley":257,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["204820339591437"],"posts_count":1},"news":{"unique_users_count":14,"unique_users":["ad_hoc_news","today_topics","cnbc","finanz_nachrichten","bloomberg","digital_journal","wall_street_online_germany","yahoo_finance_usa","business_wire","yahoo_finance_singapore","yahoo_finance_uk","device_space","el_economista","biospace"],"posts_count":32},"total":{"posts_count":36},"wikipedia":{"unique_users_count":3,"unique_users":["en:3135637","en:616967","en:63522"],"posts_count":3}},"citation":{"abstract":"Inflammatory bowel diseases (IBD) are chronic disabling gastrointestinal disorders impacting every aspect of the affected individual's life and account for substantial costs to the health care system and society. New epidemiological data suggest that the incidence and prevalence of the diseases are increasing and medical therapy and disease management have changed significantly in the last decade. An estimated 2.5-3 million people in Europe are affected by IBD, with a direct healthcare cost of 4.6-5.6 bn Euros\/year. Therefore, the aim of this review is to describe the burden of IBD in Europe by discussing the latest epidemiological data, the disease course and risk for surgery and hospitalization, mortality and cancer risks, as well as the economic aspects, patients' disability and work impairment.","abstract_source":"pubmed","altmetric_jid":"4f6fa6233cf058f610007c29","authors":["Johan Burisch","Tine Jess","Matteo Martinato","Peter L. Lakatos","on behalf of ECCO -EpiCom","Burisch J","Jess T","Martinato M","Lakatos PL"],"doi":"10.1016\/j.crohns.2013.01.010","first_seen_on":"2015-02-20T09:59:49+00:00","issns":["1876-4479","1873-9946","18739946"],"issue":"4","journal":"Journal of Crohn's and Colitis","last_mentioned_on":1495235891,"links":["http:\/\/dx.doi.org\/10.1016\/j.crohns.2013.01.010","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23395397\/","http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1873994613000305"],"pdf_url":"http:\/\/ecco-jcc.oxfordjournals.org\/content\/eccojc\/7\/4\/322.full.pdf","pmid":"23395397","pubdate":"2013-05-14T23:00:00+00:00","publisher":"The Oxford University Press","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["gastroenterology"],"title":"The burden of inflammatory bowel disease in Europe","type":"article","volume":"7","mendeley_url":"http:\/\/www.mendeley.com\/research\/burden-inflammatory-bowel-disease-europe-5"},"altmetric_score":{"score":103.25,"score_history":{"1y":34.25,"6m":0.25,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":103.25},"context_for_score":{"all":{"total_number_of_other_articles":8229276,"mean":6.9710832737933,"rank":79667,"this_scored_higher_than_pct":99,"this_scored_higher_than":8149751,"rank_type":"exact","sample_size":8229276,"percentile":99},"similar_age_3m":{"total_number_of_other_articles":210915,"mean":9.1898884000115,"rank":3185,"this_scored_higher_than_pct":98,"this_scored_higher_than":207730,"rank_type":"exact","sample_size":210915,"percentile":98},"this_journal":{"total_number_of_other_articles":770,"mean":10.232215864759,"rank":13,"this_scored_higher_than_pct":98,"this_scored_higher_than":757,"rank_type":"exact","sample_size":770,"percentile":98},"similar_age_this_journal_3m":{"total_number_of_other_articles":63,"mean":0.79274193548387,"rank":1,"this_scored_higher_than_pct":98,"this_scored_higher_than":62,"rank_type":"exact","sample_size":63,"percentile":98}}},"demographics":{"users":{"mendeley":{"by_status":{"Unspecified":3,"Professor > Associate Professor":6,"Student  > Doctoral Student":22,"Researcher":41,"Student  > Ph. D. Student":47,"Student  > Postgraduate":18,"Other":35,"Student  > Master":39,"Student  > Bachelor":40,"Lecturer":1,"Lecturer > Senior Lecturer":1,"Professor":4},"by_discipline":{"Materials Science":2,"Medicine and Dentistry":123,"Social Sciences":2,"Physics and Astronomy":2,"Psychology":2,"Sports and Recreations":1,"Unspecified":9,"Environmental Science":2,"Pharmacology, Toxicology and Pharmaceutical Science":10,"Arts and Humanities":1,"Design":1,"Engineering":4,"Chemistry":4,"Neuroscience":1,"Economics, Econometrics and Finance":2,"Immunology and Microbiology":7,"Agricultural and Biological Sciences":53,"Computer Science":1,"Nursing and Health Professions":8,"Biochemistry, Genetics and Molecular Biology":21,"Veterinary Science and Veterinary Medicine":1}}},"geo":{"mendeley":{"SG":1,"AR":1,"US":1,"IE":1,"DK":4,"GB":2,"AU":1,"ES":3}}},"posts":{"news":[{"title":"Ferring k\u00fcndigt europ\u00e4ische Markteinf\u00fchrung von CORTIMENT\u00aeMMX\u00ae bei Colitis ulcerosa an \u2013 neue Daten best\u00e4tigen erneut Sicherheit und Wirksamkeit","url":"http:\/\/www.ad-hoc-news.de\/ferring-kuendigt-europaeische-markteinfuehrung-von-cortiment-mmx-bei-colitis-ulcerosa-an-neue-daten--\/de\/News\/42060250","license":"public","citation_ids":[3716971],"posted_on":"2015-02-20T08:00:40+00:00","summary":"Ferring Pharmaceuticals hat heute die Einf\u00fchrung von CORTIMENT\u00aeMMX\u00ae (Budesonid) auf dem ...","author":{"name":"Ad Hoc News","url":"http:\/\/www.ad-hoc-news.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/201\/normal\/image.jpeg?1370251863"}},{"title":"Ferring announces European launch of CORTIMENT (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy","url":"http:\/\/www.todaytopics.com\/ferring-announces-european-launch-of-cortiment-budesonide-for-ulcerative-colitis-and-new-data-re-confirms-safety-and-efficacy\/34665\/","license":"public","citation_ids":[3716971],"posted_on":"2015-02-23T10:04:01+00:00","summary":"Ferring Pharmaceuticals has announced the European launch of CORTIMENTMMX (budesonide), the first and only approved oral controlled release budesonide treatment for active mild-to-moderate ulcerative colitis (UC) where mesalazine (5-ASA) treatment is not s","author":{"name":"Today Topics ","url":"http:\/\/www.todaytopics.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/290\/normal\/Screen_Shot_2014-11-27_at_12.02.15.png?1417089747"}},{"title":"Ergebnisse der ART-Studie aus der 48 Woche die heute auf dem amerikanischen Gastroenterologenkongress Digestive Disease Week DDW vorgestellt wurden zeigten Remissions- und Ansprechraten von 372 bzw :: AD HOC NEWS","url":"http:\/\/ct.moreover.com\/?a=26632963054&p=1pl&v=1&x=gUDFy7yAGUOzIQG5zwgWvg","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T15:30:34+00:00","summary":"Adacolumn\u00ae ist eine nicht-pharmakologische Therapie, die durch Entfernung von wei\u00dfen Blutk\u00f6rperchen aus dem Blut entz\u00fcndungshemmend wirkt.","author":{"name":"Ad Hoc News","url":"http:\/\/www.ad-hoc-news.de\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/201\/normal\/image.jpeg?1370251863"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26632970406&p=1pl&v=1&x=YR_JVQcnowsck7NktxIJNA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"Data showed remission and response rates of 37.2% and 53.2% respectively at week 12 in refractory ulcerative colitis (UC) patients treated with Adacolumn \u00ae 48-week data from the ART trial has been presented at the Digestive Disease Week (DDW\u2026","author":{"name":"CNBC","url":"http:\/\/www.cnbc.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/411\/normal\/Screen_Shot_2016-01-12_at_14.43.08.png?1452609805"}},{"title":"Studienergebnisse aus der 48. Woche - heute auf der Digestive Disease Week (DDW) vorgestellt - zeigten klinischen Vorteil mit Adacolumn in einer Subgruppe von therapierefrakt\u00e4ren Patienten mit Colitis Ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26633889075&p=1pl&v=1&x=kyrfVs67JGw14leLxonDIg","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T18:07:33+00:00","summary":"Daten zeigten Remissions- und Ansprechraten von 37,2% bzw. 53,2% in der 12. Woche bei Patienten mit therapierefrakt\u00e4rer Colitis Ulcerosa bei Behandlung mit Adacolumn Ergebnisse der 48.","author":{"name":"Finanz Nachrichten","url":"http:\/\/www.finanznachrichten.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/853\/normal\/Screen_Shot_2016-01-27_at_11.54.22.png?1453895724"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26632983317&p=1pl&v=1&x=aarqejuoFl5WWjBzDQCHqw","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"Data showed remission and response rates of 37.2% and 53.2% respectively at week 12 in refractory ulcerative colitis (UC) patients treated with Adacolumn 48-week data from the ART trial has been presented at the Digestive Disease Week (DDW) meeting\u2026","author":{"name":"Finanz Nachrichten","url":"http:\/\/www.finanznachrichten.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/853\/normal\/Screen_Shot_2016-01-27_at_11.54.22.png?1453895724"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26632987695&p=1pl&v=1&x=oIEroWfUxvCK0uzTSFVunw","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:32:59+00:00","summary":"Data showed remission and response rates of 37.2% and 53.2% respectively at week 12 in refractory ulcerative colitis (UC) patients treated with Adacolumn \u2122 48-week data from the ART trial has been presented at the Digestive Disease Week (DDW\u2026","author":{"name":"Bloomberg","url":"http:\/\/www.bloomberg.com\/europe","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/659\/normal\/Screen_Shot_2016-01-26_at_12.11.18.png?1453810324"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis - Press Release","url":"http:\/\/ct.moreover.com\/?a=26632987684&p=1pl&v=1&x=FQVZPoj6sk6WgMNwk4rEVA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:32:59+00:00","summary":"\u0001SAN DIEGO--(Business Wire)--Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"Studienergebnisse aus der 48. Woche \u2013 heute auf der Digestive Disease Week (DDW) vorgestellt \u2013 zeigten klinischen Vorteil mit Adacolumn\u00ae\u00a0in einer Subgruppe von therapierefrakt\u00e4ren Patienten mit Colitis Ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26633027260&p=1pl&v=1&x=Pxn-jNh8o-cE_GY6WzOWHQ","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"Ergebnisse der ART-Studie aus der 48. Woche, die heute auf dem amerikanischen Gastroenterologenkongress Digestive Disease Week (DDW) vorgestellt wurden, zeigten Remissions- und Ansprechraten von 37,2% bzw.","author":{"name":"Wall Street Online Germany","url":"http:\/\/www.wallstreet-online.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/837\/normal\/Screen_Shot_2016-01-27_at_11.09.05.png?1453893177"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26633045514&p=1pl&v=1&x=btGdeD18QHCsswOlV_XxwA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--(BUSINESS WIRE)-- Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"I Dati su 48 settimane presentati oggi alla Digestive Disease Week (DDW) dimostrano i benefici clinici di Adacolumn\u00ae\u00a0in un sottogruppo di pazienti refrattari affetti da colite ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26633033549&p=1pl&v=1&x=PXx0tgzUvepdR7KLnc5jrA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--I dati dello studio clinico ART a 48 settimane, presentati oggi all'evento Digestive Disease Week (DDW), dimostrano tassi di remissione e di risposta rispettivamente del 37,2% e del 53,2% alla 12ma settimana, in\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"48-veckorsdata, som idag presenterades vid sammankomsten \u201dDigestive Disease Week\u201d(DDW), p\u00e5visade klinisk nytta av Adacolumn\u00ae\u00a0i en subgrupp av patienter med ulcer\u00f6s kolit","url":"http:\/\/ct.moreover.com\/?a=26633051550&p=1pl&v=1&x=OH5xq0fSzPj25IVjPRpYeg","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--48-veckorsdata fr\u00e5n ART-studien, som idag presenterades vid sammankomsten \u201dDigestive Disease Week\u201d(DDW), p\u00e5visar en remissions- och svarsgrad p\u00e5 37,2 % respektive 53,2 % vid vecka 12 hos patienter med m\u00e5ttlig till sv\u00e5r\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Studienergebnisse aus der 48. Woche \u2013 heute auf der Digestive Disease Week (DDW) vorgestellt \u2013 zeigten klinischen Vorteil mit Adacolumn\u00ae\u00a0in einer Subgruppe von therapierefrakt\u00e4ren Patienten mit Colitis Ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26633051608&p=1pl&v=1&x=1apxiNBYWJ6mIswMiLxzKw","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--Ergebnisse der ART-Studie aus der 48. Woche, die heute auf dem amerikanischen Gastroenterologenkongress Digestive Disease Week (DDW) vorgestellt wurden, zeigten Remissions- und Ansprechraten von 37,2% bzw.","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Los datos a 48 semanas del estudio presentados hoy en la Semana de la Enfermedad Digestiva, muestran el beneficio cl\u00ednico obtenido con Adacolumn\u00ae\u00a0en un subgrupo de pacientes con colitis ulcerosa refractarios al tratamiento.","url":"http:\/\/ct.moreover.com\/?a=26633052165&p=1pl&v=1&x=kbd4qldazXXcfXGerqn0iw","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO, California (EE.UU.)--( BUSINESS WIRE )--Los datos del ensayo ART a 48 semanas, presentados hoy en la reuni\u00f3n por la Semana de la Enfermedad Digestiva (SED), han mostrado que las tasas de remisi\u00f3n y respuesta en la semana 12 fueron del 37,2\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Des donn\u00e9es sur 48\u00a0semaines pr\u00e9sent\u00e9es aujourd'hui lors d'une r\u00e9union pr\u00e9liminaire au congr\u00e8s Digestive Disease Week (DDW) d\u00e9montrent les avantages cliniques de la colonne d'aph\u00e9r\u00e8se Adacolumn\u00ae\u00a0chez un sous-groupe de patients.","url":"http:\/\/ct.moreover.com\/?a=26633052214&p=1pl&v=1&x=JKrwhQsgACMuTtURAqxcTA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )-- Des donn\u00e9es sur 48 semaines pr\u00e9sent\u00e9es aujourd'hui lors d'une r\u00e9union pr\u00e9liminaire au congr\u00e8s Digestive Disease Week (DDW) montrent les avantages cliniques de la colonne d'aph\u00e9r\u00e8se Adacolumn \u00ae chez un sous-groupe de\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26633363007&p=1pl&v=1&x=17oZA_3qESq8v3W7D3tJ_w","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( EON: Enhanced Online News )--Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Des donn\u00e9es sur 48 semaines pr\u00e9sent\u00e9es aujourd'hui lors d'une r\u00e9union pr\u00e9liminaire au congr\u00e8s Digestive Disease Week (DDW) d\u00e9montrent les avantages cliniques de la colonne d'aph\u00e9r\u00e8se Adacolumn\u00ae chez un sous-groupe de patients.","url":"http:\/\/ct.moreover.com\/?a=26634282240&p=1pl&v=1&x=r70VR-K7doIsDBGz-1sOAA","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T18:50:52+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )-- Des donn\u00e9es sur 48 semaines pr\u00e9sent\u00e9es aujourd'hui lors d'une r\u00e9union pr\u00e9liminaire au congr\u00e8s Digestive Disease Week (DDW) montrent les avantages cliniques de la colonne d'aph\u00e9r\u00e8se Adacolumn \u00ae chez un sous-groupe de\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26633090829&p=1pl&v=1&x=Pk_w76lp4DxRxDK5EmTPlQ","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--(BUSINESS WIRE)-- Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe\u2026","author":{"name":"Yahoo! Finance Singapore","url":"http:\/\/sg.finance.yahoo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/721\/normal\/Screen_Shot_2016-01-26_at_15.33.41.png?1453822448"}},{"title":"Studienergebnisse aus der 48. Woche \u2013 heute auf der Digestive Disease Week (DDW) vorgestellt \u2013 zeigten klinischen Vorteil mit Adacolumn\u00ae in einer Subgruppe von therapierefrakt\u00e4ren Patienten mit Colitis Ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26634281888&p=1pl&v=1&x=bxax17sQkgjjULlRHK_1jg","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T18:50:50+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--Ergebnisse der ART-Studie aus der 48. Woche, die heute auf dem amerikanischen Gastroenterologenkongress Digestive Disease Week (DDW) vorgestellt wurden, zeigten Remissions- und Ansprechraten von 37,2% bzw.","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"I Dati su 48 settimane presentati oggi alla Digestive Disease Week (DDW) dimostrano i benefici clinici di Adacolumn\u00ae in un sottogruppo di pazienti refrattari affetti da colite ulcerosa","url":"http:\/\/ct.moreover.com\/?a=26634281782&p=1pl&v=1&x=fixw5eLDG2MvyXtEB-8M2g","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T18:50:49+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--I dati dello studio clinico ART a 48 settimane, presentati oggi all'evento Digestive Disease Week (DDW), dimostrano tassi di remissione e di risposta rispettivamente del 37,2% e del 53,2% alla 12ma settimana, in\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"48-Week Data, Presented at the Digestive Disease Week (DDW) Meeting Today, Showed Clinical Benefit with Adacolumn\u00ae in a Sub-Group of Refractory Patients with Ulcerative Colitis","url":"http:\/\/ct.moreover.com\/?a=26633299198&p=1pl&v=1&x=EsZNovFIUGbMMClgnoDzuQ","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--(BUSINESS WIRE)-- Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe\u2026","author":{"name":"Yahoo! Finance UK ","url":"http:\/\/uk.finance.yahoo.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/686\/normal\/Screen_Shot_2016-01-26_at_14.27.25.png?1453818459"}},{"title":"Los datos a 48 semanas del estudio presentados hoy en la Semana de la Enfermedad Digestiva, muestran el beneficio cl\u00ednico obtenido con Adacolumn\u00ae en un subgrupo de pacientes con colitis ulcerosa refractarios al tratamiento.","url":"http:\/\/ct.moreover.com\/?a=26634282249&p=1pl&v=1&x=Up8B5ZI4xZaJlNBYy-fHFg","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T18:50:52+00:00","summary":"SAN DIEGO, California (EE.UU.)--( BUSINESS WIRE )--Los datos del ensayo ART a 48 semanas, presentados hoy en la reuni\u00f3n por la Semana de la Enfermedad Digestiva (SED), han mostrado que las tasas de remisi\u00f3n y respuesta en la semana 12 fueron del 37,2\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Otsuka Pharma Release 48 Week Data Presented At The Digestive Disease Week DDW Meeting Today Showed Clinical Benefit With Adacolumn In A Sub Group Of","url":"http:\/\/www.devicespace.com\/news_story.aspx?StoryID=420585&full=1","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T00:00:00+00:00","summary":"SAN DIEGO--(BUSINESS WIRE)--Data from the 48-week ART trial, presented today at the Digestive Disease Week (DDW) meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe\u2026","author":{"name":"Device Space","url":"http:\/\/www.devicespace.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/840\/normal\/Screen_Shot_2016-02-02_at_15.36.30.png?1454427403"}},{"title":"48-veckorsdata, som idag presenterades vid sammankomsten \u201dDigestive Disease Week\u201d(DDW), p\u00e5visade klinisk nytta av Adacolumn\u00ae\u00a0i en subgrupp av patienter med ulcer\u00f6s kolit","url":"http:\/\/ct.moreover.com\/?a=26635835292&p=1pl&v=1&x=ooVvwLsQCOecoTzf9TcT5w","license":"public","citation_ids":[3716971],"posted_on":"2016-05-23T16:30:00+00:00","summary":"SAN DIEGO--( BUSINESS WIRE )--48-veckorsdata fr\u00e5n ART-studien, som idag presenterades vid sammankomsten \u201dDigestive Disease Week\u201d(DDW), p\u00e5visar en remissions- och svarsgrad p\u00e5 37,2 % respektive 53,2 % vid vecka 12 hos patienter med m\u00e5ttlig till sv\u00e5r\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Los datos a 48 semanas del estudio presentados hoy en la Semana de la Enfermedad Digestiva, muestran el beneficio cl\u00ednico obtenido con Adacolumn\u00ae\u00a0en un subgrupo de pacientes con colitis ulcerosa refractarios al tratamiento","url":"http:\/\/ct.moreover.com\/?a=26640479328&p=1pl&v=1&x=4GvOiYF5HX5iKb0wPFT6-Q","license":"public","citation_ids":[3716971],"posted_on":"2016-05-24T10:05:03+00:00","summary":"- Business Wire Los datos del ensayo ART a 48 semanas, presentados hoy en la reuni\u00f3n por la Semana de la Enfermedad Digestiva (SED), han mostrado que las tasas de remisi\u00f3n y respuesta en la semana 12 fueron del 37,2% y 53,2%, respectivamente, en\u2026","author":{"name":"El Economista","url":"http:\/\/www.eleconomista.es\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/002\/298\/normal\/Screen_Shot_2016-03-09_at_10.46.19.png?1457520399"}},{"title":"Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohn\u2019s Disease","url":"http:\/\/ct.moreover.com\/?a=29621446649&p=1pl&v=1&x=r4Fo6I3QtoQhDBJBm5fbxQ","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T17:05:00+00:00","summary":"BARCELONA--( BUSINESS WIRE )--Today at the 12 th Congress of the European Crohn\u2019s and Colitis Organisation (ECCO), Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohn's Disease","url":"http:\/\/ct.moreover.com\/?a=29621460506&p=1pl&v=1&x=3O5x3VWhrSEfJHlKhGIhSQ","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T17:01:00+00:00","summary":"The primary outcome from a RCT in Crohn's disease shows biosimilar infliximab is comparable to reference infliximab in terms of efficacy and safety Today at the 12th Congress of the European Crohn's and Colitis Organisation (ECCO), Celltrion\u2026","author":{"name":"Finanz Nachrichten","url":"http:\/\/www.finanznachrichten.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/853\/normal\/Screen_Shot_2016-01-27_at_11.54.22.png?1453895724"}},{"title":"Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohn\u2019s Disease","url":"http:\/\/ct.moreover.com\/?a=29621501981&p=1pl&v=1&x=vAGykHZ0Icfl6PcIRFiGvw","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T17:11:00+00:00","summary":"BARCELONA--(BUSINESS WIRE)--Today at the 12th Congress of the European Crohn\u2019s and Colitis Organisation (ECCO), Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}},{"title":"Celltrion Healthcare Releases Positive Results From Pivotal Study In Crohn???s Disease","url":"http:\/\/ct.moreover.com\/?a=29622433904&p=1pl&v=1&x=TcQU3M6-lyvXQCNJLvpScA","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T00:00:00+00:00","summary":"BARCELONA--( BUSINESS WIRE )--Today at the 12 th Congress of the European Crohn\u2019s and Colitis Organisation (ECCO), Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab\u2026","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}},{"title":"Celltrion Healthcare pr\u00e9sente les r\u00e9sultats positifs d'une \u00e9tude pivot sur la maladie de Crohn","url":"http:\/\/ct.moreover.com\/?a=29623678325&p=1pl&v=1&x=YD2M9ftJajnxqV1dsb3v1g","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T21:31:00+00:00","summary":"BARCELONE--( BUSINESS WIRE )--Celltrion Healthcare a pr\u00e9sent\u00e9 ce jour, \u00e0 l'occasion du 12 e Congr\u00e8s de l'Organisation Europ\u00e9enne de la Maladie de Crohn et de la Colite (ECCO), le r\u00e9sultat principal de son \u00e9tude pivot comprenant un essai randomis\u00e9\u2026","author":{"name":"Business Wire","url":"http:\/\/www.businesswire.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/867\/normal\/Screen_Shot_2016-01-27_at_12.24.36.png?1453897504"}},{"title":"Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohn\u2019s Disease - Press Release","url":"http:\/\/ct.moreover.com\/?a=29621426783&p=1pl&v=1&x=GPUPqVKJxKWnAmuxb-GqVw","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T17:02:00+00:00","summary":"\u0001BARCELONA--(Business Wire)--Today at the 12 th Congress of the European Crohn\u2019s and Colitis Organisation (ECCO), Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"Celltrion Healthcare Releases Positive Results from Pivotal Study in Crohn\u2019s Disease","url":"http:\/\/ct.moreover.com\/?a=29621444622&p=1pl&v=1&x=UcnYEtLsJ0BHbDfc5Wj7Hw","license":"public","citation_ids":[3716971],"posted_on":"2017-02-17T17:00:00+00:00","summary":"BARCELONA--(BUSINESS WIRE)-- Today at the 12 th Congress of the European Crohn\u2019s and Colitis Organisation (ECCO), Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial (RCT) of CT-P13 (biosimilar infliximab\u2026","author":{"name":"Yahoo! Finance USA","url":"http:\/\/finance.yahoo.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/620\/normal\/Screen_Shot_2016-01-07_at_10.14.50.png?1452161734"}}],"wikipedia":[{"title":"Gut flora","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=721372638#altmetric_citation_fa74b56e-aac0-4f2e-9268-b55e948cda8e","license":"public","citation_ids":[3716971,3716971],"posted_on":"2016-05-21T11:38:32+00:00","summary":"Gut flora, gut microbiota, or gastrointestinal microbiota is the complex community of microorganisms that live in the digestive tracts of animals.","page_url":"http:\/\/en.wikipedia.org\/?curid=3135637","wiki_lang":"en","author":{"name":"Barbara (WVS)","url":"http:\/\/en.wikipedia.org\/wiki\/User:Barbara (WVS)"}},{"title":"Inflammatory bowel disease","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=721372707#altmetric_citation_dbc61dda-0469-4488-a825-fac73ebf971c","license":"public","citation_ids":[3716971,3716971],"posted_on":"2016-05-21T11:39:27+00:00","summary":"Inflammatory bowel disease (IBD) is a group of inflammatory conditions of the colon and small intestine.","page_url":"http:\/\/en.wikipedia.org\/?curid=616967","wiki_lang":"en","author":{"name":"Barbara (WVS)","url":"http:\/\/en.wikipedia.org\/wiki\/User:Barbara (WVS)"}},{"title":"Crohn's disease","url":"http:\/\/en.wikipedia.org\/?diff=prev&oldid=721372825#altmetric_citation_e5050bf6-ee59-43e0-a141-a15b23b2de47","license":"public","citation_ids":[3716971,3716971],"posted_on":"2016-05-21T11:41:00+00:00","summary":"Crohn's disease is a type of inflammatory bowel disease (IBD) that may affect any part of the gastrointestinal tract from mouth to anus.","page_url":"http:\/\/en.wikipedia.org\/?curid=63522","wiki_lang":"en","author":{"name":"Barbara (WVS)","url":"http:\/\/en.wikipedia.org\/wiki\/User:Barbara (WVS)"}}],"facebook":[{"title":"Untitled Album","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=1500175500055908&id=204820339591437","license":"public","citation_ids":[641536,3716971,20367242,20367243],"posted_on":"2017-05-19T23:18:11+00:00","summary":"This is why  the enslaved were denied education on slave plantations in USA, W Indies \/Europe etc and merely knowing how to read \/ being able to read no matter how poor-ly automatically, instantly brought the DEATH SENTENCE . [Just for being able to read ]","author":{"name":"None but myself can free my mind.","url":"https:\/\/www.facebook.com\/204820339591437","facebook_wall_name":"None but myself can free my mind.","image":"https:\/\/graph.facebook.com\/204820339591437\/picture","id_on_source":"204820339591437"}}]}}